Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney.
Genitourinary cancer
bladder
immune checkpoint inhibitor
kidney
prostate
tyrosine kinase inhibitor
Journal
Seminars in nephrology
ISSN: 1558-4488
Titre abrégé: Semin Nephrol
Pays: United States
ID NLM: 8110298
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
medline:
27
6
2023
pubmed:
13
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
Genitourinary cancers are diverse in their presentation, prevalence, and mortality risk. Although there have been significant advancements in medical (eg, immune checkpoint inhibitors and tyrosine kinase inhibitors) and surgical treatments of genitourinary cancers, patients are still at risk for chronic kidney disease, hypertension, and electrolyte derangements in the short and long term. In addition, pre-existing kidney disease may increase the risk of developing some genitourinary cancers. This review focuses on the kidney-related effects of treatments for renal cell carcinoma and bladder and prostate cancers.
Identifiants
pubmed: 37172546
pii: S0270-9295(23)00054-2
doi: 10.1016/j.semnephrol.2023.151344
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
151344Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.